Protease inhibitor-associated QT interval prolongation (Q37962886)

26 August 2017

Protease inhibitor-associated QT interval prolongation (English)

1 reference

26 August 2017

Kimberley Hunt

1

1 reference

26 August 2017

Christine A Hughes

series ordinal

2

1 reference

26 August 2017

Cara Hills-Nieminen

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

29 November 2011

1 reference

Annals of Pharmacotherapy

26 August 2017

1 reference

26 August 2017

45

1 reference

26 August 2017

12

1 reference

26 August 2017

1544-1550

1 reference

Changes in the risk of death after HIV seroconversion compared with mortality in the general population

26 August 2017

1 reference

Drug- and non-drug-associated QT interval prolongation

21 January 2018

1 reference

Drug-induced prolongation of the QT interval

21 January 2018

1 reference

Drug-induced QT-interval prolongation: considerations for clinicians

21 January 2018

1 reference

Long QTc and torsades de pointes in human immunodeficiency virus disease

21 January 2018

1 reference

Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection

21 January 2018

1 reference

Viral load and CD4+ cell count as risk factors for prolonged QT interval in HIV-infected subjects: a cohort-nested case-control study in an outpatient population.

21 January 2018

1 reference

Prolonged QT interval and torsades de pointes associated with atazanavir therapy

21 January 2018

1 reference

Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.

21 January 2018

1 reference

QTc interval screening in methadone treatment

21 January 2018

1 reference

Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies

21 January 2018

1 reference

Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study

21 January 2018

1 reference

Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study

21 January 2018

1 reference

Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study

21 January 2018

1 reference

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

21 January 2018

1 reference

A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients

21 January 2018

1 reference

Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q422

1 reference

26 August 2017

1 reference